ArticleOrphanet journal of rare diseases2021

Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results.

Sara Sánchez-Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.